Table of Contents
- Trial overview
- Lymphoma studies
- Neuroendocrine tumor study
- Main outcomes and what they mean
- Who can join these studies
Trial overview
The source data includes three interventional studies of Yttrium-90, all of them authorised and designed for cancer care research.[1][2][3] Two studies are in Phase 1, and one study is in Phase 3.[1][2][3] The main cancer groups studied are non-Hodgkin lymphomas, central nervous system (CNS) lymphoma, and gastrointestinal neuroendocrine tumors.[1][2][3]
Lymphoma studies
One Phase 1 study, called the COLPRIT Phase I/II study, is in people with advanced lymphoproliferative cancers, especially non-Hodgkin lymphomas (NHL).[1] It studies [90Y]Y-PentixaTher together with high-dose chemotherapy and then autoSCT, which means autologous stem cell transplant using the patient’s own stem cells.[1] The study aims to find the maximum tolerated dose in Phase I and then measure overall response rate in Phase II.[1]
Another Phase 1 study looks at [90Y]Y-PentixaTher in patients with recurrent or refractory primary or isolated secondary CNS lymphoma.[2] Recurrent means the cancer has come back, and refractory means it has not responded well to treatment.[2] This study also includes [68Ga]Ga-PentixaFor imaging and LysaKare, and it is designed to assess safety, tolerability, body distribution, and efficacy, while also finding a recommended Phase 2 dose.[2]
For this CNS lymphoma study, the listed primary outcomes include side effects, dose-limiting toxicity, changes in vital signs, laboratory values, physical exam findings, ECG findings, stem cell transplant after treatment, and mortality at 30 and 90 days after treatment.[2] These outcomes show that the study is closely tracking both short-term safety and early treatment effects.[2]
Neuroendocrine tumor study
The Phase 3 study investigates a tandem treatment approach for diagnosed and histopathologically confirmed diffuse or locally unresectable, well and intermediate differentiated neuroendocrine tumors of the gastrointestinal tract.[3] Histopathologically confirmed means the diagnosis was checked under a microscope from tissue samples.[3] The study uses DuoNEN solution for injection and aims to develop a treatment algorithm based on personalized dosimetry, which means planning treatment using patient-specific radiation measurements.[3]
The primary outcome is disease progression measured by CT or MRI using RECIST 1.1, a standard system for checking whether tumors shrink, stay stable, or grow.[3] Scans are planned after therapy at 3, 6, 12, 24, 36, 49, and 60 months, showing that this study follows patients for a long time.[3]
Main outcomes and what they mean
Across the trials, the most important outcomes are safety, dose finding, and treatment effect.[1][2][3] In the lymphoma studies, researchers measure maximum tolerated dose, overall response rate, side effects, and short-term mortality.[1][2] In the neuroendocrine tumor study, the main focus is disease progression on imaging scans over time.[3]
The studies also use imaging and laboratory checks to understand how the treatment is affecting the body.[2] These checks include vital signs, blood and urine tests, physical examination, and ECG, which is a test that records the heart’s electrical activity.[2]
Who can join these studies
Eligibility depends on the study and the cancer type.[1][2][3] The lymphoma trials include people with non-Hodgkin lymphoma or CXCR4-positive CNS lymphoma, including recurrent or refractory cases.[1][2] The Phase 3 study includes patients with diffuse or locally unresectable gastrointestinal neuroendocrine tumors that are well or intermediate differentiated.[3]
These trials are not general studies for all patients with cancer.[1][2][3] They are focused studies with specific disease types, imaging or biological targets, and clear outcome measures.[1][2][3]
